摘要
背景:动脉粥样硬化是一种慢性炎性疾病,是几种重要心血管事件,特别是冠状动脉疾病和中风的主要危险因素。动脉粥样硬化的病理过程被认为是动态和复杂的,涉及动脉内各种不同细胞类型与迁移到血管壁的细胞之间的相互作用。 目的:E1A刺激基因(CREG)的人类细胞阻遏物最初被鉴定为具有拮抗由腺病毒E1A癌蛋白诱导的转录激活和细胞转化的能力的转录因子。然而,随后的研究也将其认定为能够维持细胞内稳态并能抵抗病理性细胞和组织损伤的分泌型糖蛋白。 结果:我们证实CREG可能调节血管壁细胞的体内平衡并抑制血管组织细胞和巨噬细胞的炎症,表明CREG对炎症有潜在的保护作用。在机械上,CREG表现得像典型的可溶性溶酶体蛋白质,其通过调节小GTP酶蛋白Rab7来调节溶酶体的形成和成熟,以介导血管组织细胞中的自噬。 结论:CREG对溶酶体形成的影响可能在动脉粥样硬化中具有重要的治疗意义。
关键词: 动脉粥样硬化,自噬,E1A刺激基因的细胞阻遏物,溶酶体,冠状动脉疾病,中风
图形摘要
Current Drug Targets
Title:Cellular Repressor of E1A-stimulated Genes, A New Potential Therapeutic Target for Atherosclerosis
Volume: 18 Issue: 15
关键词: 动脉粥样硬化,自噬,E1A刺激基因的细胞阻遏物,溶酶体,冠状动脉疾病,中风
摘要: Background: Atherosclerosis is a chronic inflammatory disease and a major risk factor for several important cardiovascular events, particularly coronary artery disease and stroke. The pathological process of atherosclerosis is considered to be dynamic and complicated, involving interactions between various different cell types within arteries and the cells that migrate into the vessel wall.
Objective: Human cellular repressor of E1A-stimulated genes (CREG) was originally identified as a transcription factor with the ability to antagonize transcriptional activation and cellular transformation induced by the adenovirus E1A oncoprotein. However, subsequent studies also identified it as a secreted glycoprotein able to sustain cellular homeostasis and withstand pathological cell and tissue damage.
Results: We demonstrated that CREG may modulate homeostasis of vascular wall cells and inhibit inflammation of vascular tissue cells and macrophages, indicating a potential protective effect of CREG against inflammation. Mechanistically, CREG behaves like a typical soluble lysosomal protein that regulates the formation and maturation of lysosomes by modulating the small GTPase protein Rab7, to mediate autophagy in vascular tissue cells.
Conclusion: The impact of CREG on lysosome formation may have important therapeutic significance in atherosclerosis.
Export Options
About this article
Cite this article as:
Cellular Repressor of E1A-stimulated Genes, A New Potential Therapeutic Target for Atherosclerosis, Current Drug Targets 2017; 18 (15) . https://dx.doi.org/10.2174/1389450117666161026111250
DOI https://dx.doi.org/10.2174/1389450117666161026111250 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Influence of Dietary Substances on Intestinal Drug Metabolism and Transport
Current Drug Metabolism Comparison between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease
Current Drug Metabolism Polyphenols: A Potential New Strategy for the Prevention and Treatment of Anxiety and Depression
Current Nutrition & Food Science Myocardial Energetics in Left Ventricular Hypertrophy
Current Cardiology Reviews Multidrug Resistance Protein 4 (MRP4/ABCC4): A Suspected Efflux Transporter for Human’s Platelet Activation
Protein & Peptide Letters Small Molecules Modulating Biogenesis or Processing of microRNAs with Therapeutic Potentials
Current Medicinal Chemistry The LDL-Receptor and its Molecular Properties: From Theory to Novel Biochemical and Pharmacological Approaches in Reducing LDL-cholesterol
Current Medicinal Chemistry The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Prevalence and Prognostic Value of Depression and Anxiety in Patients with Diabetic Foot Ulcers and Possibilities of their Treatment
Current Diabetes Reviews ATP-Sensitive Potassium Channels
Current Pharmaceutical Design Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome)
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Markers of Cardiovascular Damage in Hypertension
Current Pharmaceutical Design Heart Failure
Current Hypertension Reviews Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design Editorial: Lipoprotein (a), More than Just Cholesterol?
Current Medicinal Chemistry Non Enzymatic Glycated Proteins in the Blood and Cardiovascular Disease
Current Pharmaceutical Design Adiponectin as a Target in Obesity-related Inflammatory State
Endocrine, Metabolic & Immune Disorders - Drug Targets Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients?
Current Pharmaceutical Design Fetal Arterial Changes in Response to Maternal Cigarette Smoking: Revisiting the Natural History of the Earliest Stage of Atherosclerosis
Current Cardiology Reviews The Involvement of Lysosomes in Myocardial Aging and Disease
Current Cardiology Reviews